Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 3/2021

01-03-2021 | Glucocorticoid | Vasculitis (C Dejaco & C Duftner, Section Editors)

Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis

Authors: Paride Fenaroli, Federica Maritati, Augusto Vaglio

Published in: Current Rheumatology Reports | Issue 3/2021

Login to get access

Abstract

Purpose of the Review

We aim to review the most relevant diagnostic features and treatment options of retroperitoneal fibrosis, in order to provide a useful guide for clinical practice.

Recent Findings

The recent literature highlights the role of imaging studies such as computed tomography, magnetic resonance imaging and positron emission tomography as useful tools for the diagnosis of retroperitoneal fibrosis, with retroperitoneal biopsy being reserved to atypical cases. The treatment approach is mainly conservative and is based on the use of medical therapies plus urological interventions. Medical therapies essentially comprise glucocorticoids and immunosuppressants—either traditional or biological agents such as rituximab. Surgical ureterolysis is only left for refractory cases.

Summary

Recent findings in retroperitoneal fibrosis highlight the possibility of a non-invasive diagnostic approach and a conservative treatment strategy.
Literature
1.
Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. Jan 21 2006;367(9506):241–51.
2.
van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). Jul 2009;88(4):193–201.
3.
Palmisano A, Urban ML, Corradi D, Cobelli R, Alberici F, Maritati F, et al. Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? Rheumatology (Oxford). Nov 2015;54(11):2004–9.
4.
5.
Palmisano A, Vaglio A. Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol. Jun 2009;23(3):339–53.PubMed
6.
7.
Khosroshahi A, Carruthers MN, Stone JH, Shinagare S, Sainani N, Hasserjian RP, et al. Rethinking Ormond's disease: “idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore). Mar 2013;92(2):82–91.
8.•
Maritati F, Rocco R, Accorsi Buttini E, et al. Clinical and prognostic significance of serum IgG4 in chronic periaortitis. an analysis of 113 patients. Front Immunol. 2019;10:693.The largest RPF study on the prognostic role of serum IgG4.
9.
Palmisano A, Maritati F, Vaglio A. Chronic Periaortitis: an Update. Curr Rheumatol Rep. Nov 5 2018;20(12):80.
10.
Goldoni M, Bonini S, Urban ML, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med. Aug 5 2014;161(3):181–8.
11.
Greco P, Vaglio A, Corradi D, Cobelli R, Zompatori M, Buzio C. Tuberculosis as a trigger of retroperitoneal fibrosis. Clin Infect Dis. Oct 1 2005;41(7):e72–5.
12.
Martorana D, Vaglio A, Greco P, et al. Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum. Feb 15 2006;55(1):126–30.
13.••
Martorana D, Marquez A, Carmona FD, et al. A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. J Allergy Clin Immunol. Nov 2018;142(5):1662–1665. The first demonstration on a large cohort of the association between RPF and HLADRB1*03, a marker of autoimmunity.
14.
Ramshaw AL, Roskell DE, Parums DV. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol. Aug 1994;47(8):721–7.PubMedPubMedCentral
15.
Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. Jun 2007;45(6):1538–46.PubMed
16.••
Urban ML, Maritati F, Palmisano A, et al. Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Ann Rheum Dis. 2020:433–434. vol. 3.The largest study in patients with IgG4-unrelated RPF demonstrating rituximab efficacy in difficult-to-treat cases.
17.
Wallwork R, Wallace Z, Perugino C, Sharma A, Stone JH. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore). Oct 2018;97(42):e12631.
18.
Vaglio A, Catanoso MG, Spaggiari L, Magnani L, Pipitone N, Macchioni P, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum. Sep 2013;65(9):2469–75.PubMed
19.•
Nicastro M, Vescovini R, Maritati F, et al. Fibrocytes in chronic periaortitis: a novel mechanism linking inflammation and fibrosis. Arthritis Rheumatol. Nov 2019;71(11):1913–1922.The first demonstration of fibrocytes in RPF.
20.
Zen Y, Onodera M, Inoue D, Kitao A, Matsui O, Nohara T, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. Dec 2009;33(12):1833–9.PubMed
21.
22.
Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. Apr 2011;86(4):297–303.PubMedPubMedCentral
23.
Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore). Jul 2009;88(4):202–7.
24.
Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis. Rheum Dis Clin N Am. May 2013;39(2):365–81.
25.
Palmisano A, Cobelli R, Buzio C, Vaglio A. Peri-renal collateral circles. Urology. Aug 2009;74(2):292–3.PubMed
26.
27.
Frech A, Gratl A, Fraedrich G, Glodny B, Klocker J. Periaortitis as a rare complication after endovascular aneurysm repair. Circulation. Apr 21 2015;131(16):1459–61.
28.
Pelkmans LG, Aarnoudse AJ, Hendriksz TR, van Bommel EF. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant. Jul 2012;27(7):2819–25.PubMed
29.
Vaglio A, Versari A, Fraternali A, Ferrozzi F, Salvarani C, Buzio C. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis Rheum. Feb 15 2005;53(1):122–5.
30.
Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum. May 15 2009;61(5):674–9.
31.
Fernando A, Pattison J, Horsfield C, D'Cruz D, Cook G, O'Brien T. [(18)F]-Fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. Jun 2017;71(6):926–33.PubMed
32.•
Raffiotta F, da Silva Escoli R, Quaglini S, et al. Idiopathic retroperitoneal fibrosis: long-term risk and predictors of relapse. Am J Kidney Dis. Dec 2019;74(6):742–750.A well-structured study on relapse predictors in RPF.
33.
Moriconi D, Giannese D, Capecchi R, Cupisti A, Barsotti S, Morganti R, et al. Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis. Clin Exp Nephrol. Sep 2019;23(9):1147–53.PubMed
34.
Vaglio A, Greco P, Corradi D, Palmisano A, Martorana D, Ronda N, et al. Autoimmune aspects of chronic periaortitis. Autoimmun Rev. Aug 2006;5(7):458–64.PubMed
35.
Ceresini G, Urban ML, Corradi D, Lauretani F, Marina M, Usberti E, et al. Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: a case-control study. Autoimmun Rev. Jan 2015;14(1):16–22.PubMed
36.
Cronin CG, Lohan DG, Blake MA, Roche C, McCarthy P, Murphy JM. Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol. Aug 2008;191(2):423–31.PubMed
37.
George V, Tammisetti VS, Surabhi VR, Shanbhogue AK. Chronic fibrosing conditions in abdominal imaging. Radiographics. Jul-Aug 2013;33(4):1053–80.PubMed
38.
Pipitone N, Versari A, Vaglio A, Salvarani C. Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis. Clin Exp Rheumatol. Jan-Feb 2011;29(1 Suppl 64):S72–8.PubMed
39.
Akhan SE, Dogan Y, Akhan S, Iyibozkurt AC, Topuz S, Yalcin O. Pelvic actinomycosis mimicking ovarian malignancy: three cases. Eur J Gynaecol Oncol. 2008;29(3):294–7.PubMed
40.
Gianfreda D, Musetti C, Nicastro M, Maritati F, Cobelli R, Corradi D, et al. Erdheim-Chester disease as a mimic of IgG4-related disease: a case report and a review of a single-center cohort. Medicine (Baltimore). May 2016;95(21):e3625.
41.
Urban ML, Palmisano A, Nicastro M, Corradi D, Buzio C, Vaglio A. Idiopathic and secondary forms of retroperitoneal fibrosis: a diagnostic approach. Rev Med Interne. Jan 2015;36(1):15–21.PubMed
42.
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. Feb 9 2012;366(6):539-.
43.
Vaglio A, Strehl JD, Manger B, Maritati F, Alberici F, Beyer C, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis. Mar 2012;71(3):390–3.PubMed
44.
Koo BS, Koh YW, Hong S, Kim YJ, Kim YG, Lee CK, et al. Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod Rheumatol. Mar 2015;25(2):194–8.PubMed
45.
Pelkmans LG, Hendriksz TR, Westenend PJ, Vermeer HJ, van Bommel EFH. Elevated serum IgG4 levels in diagnosis and treatment response in patients with idiopathic retroperitoneal fibrosis. Clin Rheumatol. Apr 2017;36(4):903–12.PubMed
46.
Castelein T, Coudyzer W, Blockmans D. IgG4-related periaortitis vs idiopathic periaortitis: is there a role for atherosclerotic plaque in the pathogenesis of IgG4-related periaortitis? Rheumatology (Oxford). Jul 2015;54(7):1250–6.
47.
Kim IY, Eun YH, Jeong H, Park TK, Kim H, Lee J, et al. Clinical characteristics and outcomes of 61 patients with chronic periaortitis including IgG4-related and non-IgG4-related cases. Int J Rheum Dis. Nov 2017;20(11):1751–62.PubMed
48.
Kottra JJ, Dunnick NR. Retroperitoneal fibrosis. Radiol Clin N Am. Nov 1996;34(6):1259–75.PubMed
49.
Bakir B, Yilmaz F, Turkay R, Özel S, Bilgiç B, Velioglu A, et al. Role of diffusion-weighted MR imaging in the differentiation of benign retroperitoneal fibrosis from malignant neoplasm: preliminary study. Radiology. Aug 2014;272(2):438–45.PubMed
50.
Mirault T, Lambert M, Puech P, Argatu D, Renaud A, Duhamel A, et al. Malignant retroperitoneal fibrosis: MRI characteristics in 50 patients. Medicine (Baltimore). Sep 2012;91(5):242–50.
51.
Jansen I, Hendriksz TR, Han SH, Huiskes AW, van Bommel EF. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med. Jun 2010;21(3):216–21.PubMed
52.
Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, et al. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging. Oct 2012;39(10):1635–42.PubMed
53.
Salvarani C, Pipitone N, Versari A, et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum. Apr 15 2005;53(2):298–303.
54.
Wang Y, Guan Z, Gao D, Luo G, Li K, Zhao Y, et al. The value of (18)F-FDG PET/CT in the distinction between retroperitoneal fibrosis and its malignant mimics. Semin Arthritis Rheum. Feb 2018;47(4):593–600.PubMed
55.•
Accorsi Buttini E, Maritati F, Vaglio A. [(18)F]-Fluorodeoxyglucose positron emission tomography and response to therapy in idiopathic retroperitoneal fibrosis. Eur Urol. Jan 2018;73(1):145-146. A study on a large cohort of RPF patients focusing on the role of PET in predicting response to therapy.
56.
Vaglio A, Greco P, Versari A, Filice A, Cobelli R, Manenti L, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol. Mar-Apr 2005;23(2):231–4.PubMed
57.
Morin G, Mageau A, Benali K, Bertinchamp R, Piekarski E, Raimbourg Q, et al. Persistent FDG/PET CT uptake in idiopathic retroperitoneal fibrosis helps identifying patients at a higher risk for relapse. Eur J Intern Med. Apr 2019;62:67–71.PubMed
58.
Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford). Feb 1 2018;57(suppl_2):ii32-ii42.
59.
Abe H, Morikawa T, Araki A, et al. IgG4-related periureteral fibrosis presenting as a unilateral ureteral mass. Pathol Res Pract. Nov 15 2011;207(11):712–4.
60.
Ellimoottil C, Hart S, Mehta V, Quek ML. Localized perirenal retroperitoneal fibrosis. Urology. Apr 2013;81(4):e27–8.PubMed
61.
Jois RN, Gaffney K, Marshall T, Scott DG. Chronic periaortitis. Rheumatology (Oxford). Nov 2004;43(11):1441–6.
62.
Mertens S, Zeegers AG, Wertheimer PA, Hendriksz TR, van Bommel EF. Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction. Int J Urol. Mar 2014;21(3):283–8.PubMed
63.
Srinivasan AK, Richstone L, Permpongkosol S, Kavoussi LR. Comparison of laparoscopic with open approach for ureterolysis in patients with retroperitoneal fibrosis. J Urol. 2008;179(5):1875–8.PubMed
64.
Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. Jul 23 2011;378(9788):338–46.
65.
van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis. May 2007;49(5):615–25.PubMed
66.
van Bommel EF. Retroperitoneal fibrosis. Neth J Med. Jul 2002;60(6):231–42.PubMed
67.
van Bommel EF, van Spengler J, van der Hoven B, Kramer P. Retroperitoneal fibrosis: report of 12 cases and a review of the literature.
68.
Kardar AH, Kattan S, Lindstedt E, Hanash K. Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol. 2002;168(2):550–5.PubMed
69.
Cogan E, Fastrez R. Azathioprine. An alternative treatment for recurrent idiopathic retroperitoneal fibrosis. Arch Intern Med. Apr 1985;145(4):753–5.PubMed
70.
Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med. Feb 1 2004;116(3):194–7.
71.
Harreby M, Bilde T, Helin P, Meyhoff HH, Vinterberg H, Nielsen VA. Retroperitoneal fibrosis treated with methylprednisolon pulse and disease-modifying antirheumatic drugs. Scand J Urol Nephrol. Sep 1994;28(3):237–42.PubMed
72.
Grotz W, von Zedtwitz I, Andre M, Schollmeyer P. Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet. 1998:1195. vol. 9135.
73.
Jois RN, Kerrigan N, Scott DG. Mycophenolate mofetil for maintenance of remission in idiopathic retroperitoneal fibrosis. Rheumatology (Oxford). 2007:717–8. vol. 4.
74.
Marzano A, Trapani A, Leone N, Actis GC, Rizzetto M. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis. Apr 2001;60(4):427–8.PubMedPubMedCentral
75.
Al-Harthy F, Esdaile J, Berean KW, Chalmers A. Multifocal idiopathic fibrosclerosis: treatment of 2 cases with cyclosporine. J Rheumatol. 2006;33(2):358–61.PubMed
76.
Scheel PJ Jr, Piccini J, Rahman MH, Lawler L, Jarrett T. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol. 2007;178(1):140–3 discussion 143-4.PubMed
77.
Scheel PJ, Jr., Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. Jan 4 2011;154(1):31–6.
78.
Scavalli AS, Spadaro A, Riccieri V, Ricciuti GP, Taccari E, Marini M, et al. Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clin Rheumatol. Jul 1995;14(4):481–4.PubMed
79.
Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis. 2013:1584–6. vol. 9.
80.
Maritati F, Corradi D, Versari A, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis. 2012:1262–4. vol. 7.
81.
Benucci M, Damiani A, Li Gobbi F, et al. Jaccoud’s arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment. Reumatismo. Aug 3 2017;69(2):88–91.
82.
Loricera J, Blanco R, Castaneda S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol. May-Jun 2014;32(3 Suppl 82):S79–89.PubMed
83.
Perrotta FM, Fici M, Guerra G, Brunese L, Salvarani C, Lubrano E. Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report. Clin Exp Rheumatol. 2017:226–227. vol. 1.
84.
Moroni G, Gallelli B, Banfi G, Sandri S, Messa P, Ponticelli C. Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol Dial Transplant. Sep 2006;21(9):2485–90.PubMed
85.
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. Nov 6 2014;371(19):1771–80.
Metadata
Title
Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis
Authors
Paride Fenaroli
Federica Maritati
Augusto Vaglio
Publication date
01-03-2021
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 3/2021
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-020-00966-9

Other articles of this Issue 3/2021

Current Rheumatology Reports 3/2021 Go to the issue

Reactive Arthritis (H Zeidler, Section Editor)

Update on Post-Streptococcal Reactive Arthritis: Narrative Review of a Forgotten Disease

Vasculitis (C Dejaco and C Duftner, Section Editors)

Clinical Approach to Diagnosis and Therapy of Polyarteritis Nodosa

Osteoarthritis (M Goldring and T Griffin, Section Editors)

Metabolic Regulation of Tendon Inflammation and Healing Following Injury

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Systemic Lupus Erythematosus in Children and Young People

Vasculitis (C Dejaco and C Duftner, Section Editors)

Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

A Review of Complement Activation in SLE
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits